Business Context and Reporting Period
This Form 8-K reports on the 2022 Annual Meeting of Stockholders held by Keros Therapeutics, Inc. on June 1, 2022. The company is an emerging growth company incorporated in Delaware with its principal executive offices in Lexington, Massachusetts.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Stockholders elected Ran Nussbaum and Mary Ann Gray to serve until the 2025 Annual Meeting.
- Ran Nussbaum: 18,330,118 votes for; 1,822,787 votes withheld.
- Mary Ann Gray: 18,332,369 votes for; 1,820,536 votes withheld.
- Proposal 2 (Ratification of Auditors): Stockholders approved the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Votes For: 16,436,641
- Votes Against: 0
- Votes Abstain: 3,665,697
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation that Ran Nussbaum and Mary Ann Gray have assumed their director roles effective immediately following the June 1, 2022 meeting.
- Verification that Deloitte & Touche LLP is officially engaged as the auditor for the fiscal year ending December 31, 2022.
- Review of the definitive proxy statement filed on April 18, 2022, for detailed background on the nominees and auditor selection rationale.